Cellectis S A 's

The company faces competitive risks related to regulatory approvals, patent protection, and intellectual property enforcement. It is developing novel allogeneic CAR T-cell immunotherapy product candidates, which are subject to uncertain regulatory requirements that may delay development or increase costs. The loss of orphan drug exclusivity could enable competitors to market the same drugs, potentially reducing revenues. Patent protection is essential; however, lapses or failure by licensors to maintain or enforce patents could weaken the company's competitive position. Competitors with greater financial resources and more extensive intellectual property portfolios may be better equipped to sustain litigation costs, posing challenges to the company's intellectual property rights. Additionally, trade secret protection is important but difficult to maintain, and unauthorized disclosures could adversely affect the company's competitive standing.